AHA yesterday sent a letter to the Department of Justice’s Antitrust Division expressing its serious concern with the adequacy of any remedy to resolve the anticompetitive impact of UnitedHealth Group’s acquisition of Change Healthcare. UHG in January announced its intent to combine its Optum health services subsidiary with Change Healthcare, a health care technology firm, to provide software and data analytics, technology-enabled services and research, advisory and revenue cycle management services.

At the time, AHA argued that the deal would distort “decisions about patient care and claims processing and denials to the detriment of consumers and health care providers and further increase UHG’s already massive market power.” In the newest letter AHA reiterated that “it is highly unlikely that any remedy will preserve the substantial level of competition between the parties that will be lost if the transaction is completed.”

Related News Articles

Headline
The White House Feb. 1 announced it placed tariffs on imported goods from Canada, Mexico and China. The tariffs for Mexico and Canada have since been delayed…
Headline
The AHA Jan. 28 voiced support for bipartisan legislation to reauthorize for five years the Dr. Lorna Breen Health Care Provider Protection Act, which provides…
Chairperson's File
There is so much for health care leaders to navigate when it comes to public policy and government relations. Thankfully, the AHA has an expert team with…
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that…
Perspective
All eyes this week have been on Washington, D.C., as President Trump was inaugurated and the 119th Congress — with Republicans holding majorities in the House…
Headline
The AHA yesterday released its 2025 Advocacy Agenda that details the association's key priorities for Congress, the Administration, regulatory agencies and…